Pfizer and Ionis Pharmaceuticals are discontinuing a joint study of the candidate drug vupanorsen. The drug was being developed as a drug to reduce the risk of cardiovascular disease and severe hypertriglyceridemia. Pfizer will return the development rights to Ionis.